Although the treatment and drug discovery for Alzheimer’s disease (AD) are limited and some have failed recently, the search for potential biomarkers and early predictors continue.AD is not only characterized by the decline of episodic memory, but also by amnestic mild cognitive impairment (aMCI) that deserves more attention.MCI is a positive prodrome of subsequent AD, and the rate of conversion to AD can rise to 50％ at 2-3 years from the initial stage.It has been reported that, after 6 years, 61 out of 76 MCI patients (mean age =81 years) converted to AD [1, 2].The assessment of visuospatial abilities, which are necessary pre-requisites of independent mobility in the environment, is crucial to monitor elderly people’s wellbeing.Navigational impairment in AD patients has been linked to a disorder of extrastriate visual cortical motion processing that is reflected in specific perceptual and memory measures of spatial abilities [3].